The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
Apple bought Tueo Health, which was developing tech to help parents monitor asthma symptoms in children, using a mobile app and commercial breathing sensors.Technologyread more
United Airlines will take its 14 Boeing 737 Max jets off its schedule for another month, through Aug. 3, canceling another 1,290 flights.Airlinesread more
Trade could be a big factor for markets in the week ahead, but investors will also be attuned to fresh inflation data and the bond market, which is flashing new worries about...Market Insiderread more
Mississippi is one of several states that have moved to pass new restrictions on abortion this year.Politicsread more
"You got to look around the corner," said Martine Rothblatt, who earlier in her career started Sirius Radio, which later merged with XM to form Sirius XM. "Today our business is all about pharmaceuticals. But in the 2020s, I think you're going to see a transition ... to regenerative medicine — tissues, beyond cell therapies, and then whole organs."
In collaboration with genome sequencing pioneer J. Craig Venter and his firm Synthetic Genomics, United Therapeutics is working on lab-grown organs.
"Our company is well positioned. We [also] own the U.S. arm of the Dolly the Sheep company, The Roslin Institute," Rothblatt said on "Squawk Box." Dolly was the world's first mammal to be cloned from an adult cell.
"All [organs] are readily doable," she said. "In fact, they're already being tested in baboons, which is a model for the human. We have hearts at [National Institutes of Health] NIH now. Our hearts last over two years in the baboons. "
Rothblatt started United Therapeutics in 1996 to help find a cure for her daughter's pulmonary hypertension. The firm currently has four drugs on the market to treat the disease.
Along with other biotech stocks, United Therapeutics has had a tough year, down nearly 30 percent in 2016. But that's nearly double the decline of the iShares Nasdaq Biotechnology ETF. United Therapeutics has market value of nearly $5 billion.
The stock price notwithstanding, Rothblatt see big things ahead. "There are some far-sighted investors that say, 'Hey, I have a chance to get in on ... [an] Amgen before it was Amgen; or ... Google before it was big.' "
Admitting it's early days for lab-grown organs, Rothblatt maintained a commercial product might not be that far off.
"We'll have the first transplantable organs in patients before the end of this decade, before the end of 2019," she predicted. "[Then] I would say FDA approval around 2023."
Rothblatt was thrust into the spotlight in 2014, after it was revealed she was the highest paid female executive in America, with a 2013 pay package of $38 million.
At the time, Rothblatt told Fortune she felt awkward from the attention because she's only been a women for half of her life. In 1994, she underwent sex-reassignment surgery.